eMedicine Specialties > Dermatology > Benign Neoplasms

Atypical Fibroxanthoma: Differential Diagnoses & Workup

Author: Forrest C Brown, MD, Clinical Professor of Dermatology, University of Texas Southwestern Medical School; Section Chief, Department of Dermatology, Medical City Dallas Hospital
Contributor Information and Disclosures

Updated: Aug 7, 2009

Differential Diagnoses

Dermatofibrosarcoma Protuberans
Malignant Melanoma
Squamous Cell Carcinoma

Other Problems to Be Considered

Spindle cell squamous cell carcinoma
Spindle cell malignant melanoma
Superficial portion of a malignant fibrous histiocytoma
Leiomyosarcoma

Workup

Laboratory Studies

  • Panels of antibodies
  • Electron microscopy
  • DNA content quantification

Histologic Findings

The pathologic appearance of atypical fibroxanthoma (AFX) belies the usually excellent prognosis. As shown in the image below, this nonencapsulated dermal tumor is composed of large, fibrocytic, spindle-shaped and anaplastic cells arranged in a haphazard fashion, occasionally in fascicles, and usually with an increased number of mitotic figures. Large histiocytic cells may form bizarre multinucleated giant cells that frequently contain lipid, contributing to the tumor's name. Phagocytosis of erythrocytes has been demonstrated, resulting in hemosiderin pigmentation within a lesion and causing clinical confusion with malignant melanoma. Granular and clear cell variants have recently been reported.
 

Microscopic view of atypical fibroxanthoma. Note ...

Microscopic view of atypical fibroxanthoma. Note the large abnormal-appearing cells in a field of spindle cells. Courtesy of Capt James Steger, MC, USN, US Naval Hospital, San Diego.

Microscopic view of atypical fibroxanthoma. Note ...

Microscopic view of atypical fibroxanthoma. Note the large abnormal-appearing cells in a field of spindle cells. Courtesy of Capt James Steger, MC, USN, US Naval Hospital, San Diego.


Electron microscopy

Electron microscopy suggests a fibrohistiocytic nature in the tumor. A transition from fibroblast to large giant cells can be seen, with intermediate forms that exhibit features of both cell types. Pathologic findings in AFX appear to be more related to MFH than to either dermatofibroma or dermatofibrosarcoma protuberans (DFSP). Delicate cytoplasmic fibrils were seen in one case studied with electron microscopy, but these fibrils were not considered to arise from myofibroblasts and findings did not support a muscle origin for AFX.

Immunohistochemistry

Panels of specific antibodies together with the tumor's histologic pattern help differentiate AFX from other types of spindle cell skin lesions. Specific and critical differences of antibody reactivity (R) and nonreactivity (N) are demonstrated in the Table.

Antibody Panels in Tumors

Open table in new window

Table
AntibodyAFXMFHSCCDFSPSpindle
MM*
Leiomyosarcoma
VimentinRRNRRR
CytokeratinNNRNNN
S-100NNNNRN
Desmin or smooth muscle actinNNNNNR
AntibodyAFXMFHSCCDFSPSpindle
MM*
Leiomyosarcoma
VimentinRRNRRR
CytokeratinNNRNNN
S-100NNNNRN
Desmin or smooth muscle actinNNNNNR

*Spindle cell malignant melanoma

New published data indicate that LN-2 antibody (CD74) and p53 immunoreactivity may help differentiate between malignant lesions in the fibrohistiocytic series, but further confirmation is needed. SCC, spindle cell MM, and leiomyosarcoma usually are differentiated using immunocytochemistry. No reliable consistent immunocytochemistry method is specific for AFX, and the diagnosis is based on typical histologic findings and the absence of immunomarker positivity for melanocytes, keratin, and smooth muscle actin.

DNA content quantification

Diploid or euploid cells have pairs or multiple pairs of chromosomes and usually are considered benign. Aneuploid cells have single or multiple single sets of chromosomes and are more common in malignant neoplasms.

Attempts to evaluate chromatin content in AFX have resulted in much confusion because of the methods of evaluation. The average picture produced with flow cytometry suggests that AFX is diploid. Using individual cell analysis, aneuploidy was found in giant cells, while diploidy has been found in smaller spindle-shaped cells. This picture is similar to MFH and does not allow nuclear cytometry to differentiate between MFH and AFX.

Histologic variants

Nonpleomorphic AFX (spindle cell AFX) was reported by Wilson-Jones et al in a series of cases of sun-damaged skin of the head and neck in older individuals. The immunocytochemistry findings and the tumors' benign clinical course supported the diagnosis of AFX. Pathologically, lesions were monomorphic, spindle-celled, fascicular variants without pleomorphic cells. All lesions were vimentin positive with approximately 50% showing focal actin activity. Desmin, keratin, and S-100 protein were negative in all cases.

More on Atypical Fibroxanthoma

Overview: Atypical Fibroxanthoma
Differential Diagnoses & Workup: Atypical Fibroxanthoma
Treatment & Medication: Atypical Fibroxanthoma
Follow-up: Atypical Fibroxanthoma
Multimedia: Atypical Fibroxanthoma
References

References

  1. Zalla MJ, Randle HW, Brodland DG, et al. Mohs surgery vs wide excision for atypical fibroxanthoma: follow-up. Dermatol Surg. Dec 1997;23(12):1223-4. [Medline].

  2. Ang GC, Roenigk RK, Otley CC, Kim Phillips P, Weaver AL. More than 2 decades of treating atypical fibroxanthoma at mayo clinic: what have we learned from 91 patients?. Dermatol Surg. May 2009;35(5):765-72. [Medline].

  3. Calonje E, Wadden C, Wilson-Jones E, Fletcher CD. Spindle-cell non-pleomorphic atypical fibroxanthoma: analysis of a series and delineation of a distinctive variant. Histopathology. Mar 1993;22(3):247-54. [Medline].

  4. Champion R, Burton JL, Burns DA, Breathnach SM, eds. Rook/Wilkinson/Ebling Textbook of Dermatology. Vol 3. 6th ed. Oxford: Blackwell Science;1998:2352-3.

  5. Diaz-Cascajo C, Borghi S, Bonczkowitz M. Pigmented atypical fibroxanthoma. Histopathology. Dec 1998;33(6):537-41. [Medline].

  6. Fish FS. Soft tissue sarcomas in dermatology. Dermatol Surg. Mar 1996;22(3):268-73. [Medline].

  7. Giuffrida TJ, Kligora CJ, Goldstein GD. Localized cutaneous metastases from an atypical fibroxanthoma. Dermatol Surg. Dec 2004;30(12 Pt 2):1561-4. [Medline].

  8. Grosso M, Lentini M, Carrozza G, Catalano A. Metastatic atypical fibroxanthoma of skin. Pathol Res Pract. Jun 1987;182(3):443-7. [Medline].

  9. Hafner J, Kunzi W, Weinreich T. Malignant fibrous histiocytoma and atypical fibroxanthoma in renal transplant recipients. Dermatology. 1999;198(1):29-32. [Medline].

  10. Lazova R, Moynes R, May D, Scott G. LN-2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma. Cancer. Jun 1 1997;79(11):2115-24. [Medline].

  11. Lee CS, Chou ST. p53 protein immunoreactivity in fibrohistiocytic tumors of the skin. Pathology. Aug 1998;30(3):272-5. [Medline].

  12. Leong AS, Milios J. Atypical fibroxanthoma of the skin: a clinicopathological and immunohistochemical study and a discussion of its histogenesis. Histopathology. May 1987;11(5):463-75. [Medline].

  13. Ma CK, Zarbo RJ, Gown AM. Immunohistochemical characterization of atypical fibroxanthoma and dermatofibrosarcoma protuberans. Am J Clin Pathol. Apr 1992;97(4):478-83. [Medline].

  14. Michie BA, Reid RP, Fallowfield ME. Aneuploidy in atypical fibroxanthoma: DNA content quantification of 10 cases by image analysis. J Cutan Pathol. Oct 1994;21(5):404-7. [Medline].

  15. Requena L, Sangueza OP, Sanchez Yus E, Furio V. Clear-cell atypical fibroxanthoma: an uncommon histopathologic variant of atypical fibroxanthoma. J Cutan Pathol. Mar 1997;24(3):176-82. [Medline].

  16. Rudisaile SN, Hurt MA, Santa Cruz DJ. Granular cell atypical fibroxanthoma. J Cutan Pathol. Apr 2005;32(4):314-7. [Medline].

  17. Silvis NG, Swanson PE, Manivel JC, et al. Spindle-cell and pleomorphic neoplasms of the skin. A clinicopathologic and immunohistochemical study of 30 cases, with emphasis on "atypical fibroxanthomas". Am J Dermatopathol. Feb 1988;10(1):9-19. [Medline].

  18. Starink TH, Hausman R, Van Delden L, Neering H. Atypical fibroxanthoma of the skin. Presentation of 5 cases and a review of the literature. Br J Dermatol. Aug 1977;97(2):167-77. [Medline].

  19. Wilson PR, Strutton GM, Stewart MR. Atypical fibroxanthoma: two unusual variants. J Cutan Pathol. Apr 1989;16(2):93-8. [Medline].

  20. Worrell JT, Ansari MQ, Ansari SJ, Cockerell CJ. Atypical fibroxanthoma: DNA ploidy analysis of 14 cases with possible histogenetic implications. J Cutan Pathol. Jun 1993;20(3):211-5. [Medline].

Further Reading

Keywords

atypical fibroxanthoma, AFX, sun exposure, photodamage, skin cancer, malignant fibrous histiocytoma, MFH, squamous cell carcinoma, squamous cell cancer, SCC, melanoma, nodular melanoma, sun damage, radiation exposure, radiation damage

Contributor Information and Disclosures

Author

Forrest C Brown, MD, Clinical Professor of Dermatology, University of Texas Southwestern Medical School; Section Chief, Department of Dermatology, Medical City Dallas Hospital
Disclosure: Nothing to disclose.

Medical Editor

Carrie L Kovarik, MD, Assistant Professor of Dermatology, Dermatopathology, and Infectious Diseases, University of Pennsylvania School of Medicine
Carrie L Kovarik, MD is a member of the following medical societies: Alpha Omega Alpha
Disclosure: Nothing to disclose.

Pharmacy Editor

Richard P Vinson, MD, Assistant Clinical Professor, Department of Dermatology, Texas Tech University School of Medicine; Consulting Staff, Mountain View Dermatology, PA
Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Association of Military Dermatologists, Texas Dermatological Society, and Texas Medical Association
Disclosure: Nothing to disclose.

Managing Editor

Rosalie Elenitsas, MD, Herman Beerman Associate Professor of Dermatology, University of Pennsylvania School of Medicine; Director, Penn Cutaneous Pathology Services, Department of Dermatology, University of Pennsylvania Health System
Rosalie Elenitsas, MD is a member of the following medical societies: American Academy of Dermatology and American Society of Dermatopathology
Disclosure: Nothing to disclose.

CME Editor

Joel M Gelfand, MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
Joel M Gelfand, MD, MSCE is a member of the following medical societies: Society for Investigative Dermatology
Disclosure: AMGEN Consulting fee Consulting; AMGEN Grant/research funds Investigator; Genentech Grant/research funds investigator; Centocor Consulting fee Consulting; Abbott Grant/research funds investigator; Abbott Consulting fee Consulting; Novartis  investigator; Pfizer Grant/research funds investigator; Celgene Consulting fee DMC Chair; NIAMS and NHLBI Grant/research funds investigator

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

RELATED MEDSCAPE ARTICLES
Articles
 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.